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small fields and challenges in multicentre comparison of 
gamma analysis for complex dose distributions.  
Overall, the IAEA supports developments of various audit 
tools for radiotherapy with the audit scope corresponding to 
the evolving complexity of radiotherapy technology, in order 
to verify radiotherapy physics practices and improve the 
quality of treatments delivered to cancer patients in 
participating countries. 
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This presentation will focus on the main differences between 
the radiotherapy treatment planning with photons and 
protons. An important issue in all treatment planning is the 
dosimetric uncertainties and margins to account for these. 
Compared to photons, protons have additional sources of 
uncertainties that should be analysed and understood. 
Insufficient quantification of margins can have more serious 
consequences in proton therapy than is the case for photons.  
The main advantage of proton beams is the finite range and 
sharp distal dose fall off in depth, an advantage that often is 
a contradiction in the sense that the range uncertainty limits 
the use of this advantage. A second advantage is the ability 
to, with every single field, give the target volume a higher 
dose than the surrounding tissue. The sources of range 
uncertainties are caused by the patient variations in anatomy 
and the uncertainties in the conversion of CT numbers to 
tissues with the correct proton interaction properties. The 
handling of range uncertainties play a critical role in proton 
planning and has an impact on the entire treatment planning 
process that differs from photons.  
The generic PTV margin recipes used in photon planning, are 
not adequate in proton planning. Primarily, this is used to 
account for lateral beam uncertainties. In proton planning, 
two margins have to be considered, the lateral and the 
margin in depth i.e. range uncertainty. In principle, these 
two margins arises from different physical processes. 
According to ICRU 78 [1] the PTVs are recommended to be 
used in proton planning for dose reporting purposes. 
Additional volumes with beam specific margins, have to be 
used to account for uncertainties in range. Paganetti has 
suggested margin recipes that is widely used in proton 
planning [2].  
Consequently, the range uncertainty also has an influence on 
the selection of beam and their entry angles. In this phase of 
the treatment planning process, proton planning emphasizes 
other considerations than photons. Robust planning has the 
potential of mitigate the impact of range uncertainties, 
aiming for a robust beam path i.e. heterogeneous geometry 
along the beam path. Likewise, the robustness should be 
considered during the optimization as well as during the 
treatment plan evaluation and the comparison with a photon 
treatment plan to choose the best treatment plan.  
The contents of this presentation are based on experiences 
from the start-up of the first Scandinavian Proton Centre, 
Skandionkliniken, where the first patients were treated in 
late august 2015. Nearly four years before that, in January 
2012, we started the Proton School in order to prepare for 
the clinical start and to train a group of medical physicists, 
dosimetrists and radiation oncologists in proton planning 
[3,4]. Thinking protons instead of photons has been the 
greatest challenge for the group as a whole. How do we 
achieve the best plan? This includes selecting robust beam 
angles and thinking about what the protons interact with on 
its way to the target volume. Discussions about target 
volumes has been frequent, as the use of them. Delineation 
is a major issue, not only for CTV/PTV but for other 
structures the protons might interact with in its beam path, 
as well as optimisation structures to provide the best 
treatment plan.  
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Anatomical changes are important issue during radiotherapy 
because they could potentially lead to inadequate dose 
distribution to target and organs at risk (OAR). Radiation 
induced complications have a significant adverse impact on 
health-related quality of life. To minimize the risk adaptive 
radiotherapy (ART) has become state of art of modern 
radiotherapy. In clinical practice ART is expressed mostly by 
Image-Guided Radiation Therapy (IGRT) and re-planning, the 
last is very individualized but should be more unified. Clear 
guidelines are therefore needed to determine the timing of 
re-planning, and an increasing amount of information needs 
to be acquainted, transferred and stored.  
There are several indications that anatomic changes are more 
pronounced in the first half of treatment, and therefore 
repeated imaging and replanning should be performed in this 
first time period.The parotid gland was the most studied OAR 
and showed the largest volume changes during radiotherapy 
(26% average volume decrease). The average number of 
radiation fractions delivered between baseline and re-
planning CT scans was 15 (±5) fractions which equals 21 (±8) 
days. It is also well established in the Head and neck (H&N) 
area that, because of i.e. weight loss and/or tumor shrinkage 
especially in more advanced stages of cancer (T3/T4, large 
N+), re-planning improves relapse–free survival and 
significantly alleviated the late effects. In many dosimetric 
studies without replanning during treatment, the doses to 
normal structures were significantly increased and doses to 
target volume significantly decreased. According to literature 
replanning frequency increases also with smaller PTV 
margins.  
To answer the question „When to re-plan?” we need to know 
which sites would most benefit. In regard to literature 
studies it seems that re-plan would be the most beneficial for 
tumors of the biggest volume or the nearest proximity of the 
OAR’s. Still it does not explain „when” should we perform it. 
Despite of the great amount of reports and analysis further 
research are needed. 
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Purpose/Objective: Labor-intensive procedures, such as 
adaptive radiotherapy, result in an increased workload in the 
treatment planning department, which can be reduced by 
introducing fully automated treatment planning. The benefits 
of automated planning are many: reduction of workload, 
increased workflow efficiency, and reduction of plan 
variability. However, a potential pitfall could be loss of 
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knowledge and skills among RTTs, leading to less ability to 
design, judge or adapt treatment plans. The purpose of this 
work is to show the capabilities of automatic planning and 
discuss its consequence for a radiation-oncology department.  
 
Material and Methods: At the NKI a project was started to 
develop single-click treatment planning for techniques based 
on a class solution. Technically this was accomplished by 
separating medical planning protocol definition from actual 
control of the treatment planning system (Pinnacle3, version 
9.10, Philips Medical Systems). After target delineation, a 
single mouse-click initiates the following actions: Pinnacle 
patient record generation, auto-segmentation of organs at 
risk (OARs), beam setup, optimization of the dose 
distribution, and creation of PDF documentation. The plan is 
then ready for inspection by RTT and physician. This 
procedure is currently implemented into our clinic for 
prostate, breast and vertebral metastases. Currently, 
knowledge and skills among RTTs is primarily maintained by 
the requirement to perform a certain number of treatment 
plans per year for a given tumor site. In addition, all 
treatment plans are checked by a second RTT, and feedback 
is given on deviations from protocol and/or possibilities to 
improve the plan. Finally, special cases are discussed with all 
RTTs on a monthly basis.  
 
Results: A fully automated treatment plan requires 20 
minutes for prostate and breast, and 7 minutes for vertebral 
metastases. Up to now, 185 patients have received a fully 
automated treatment planning procedure. In about 15% of 
the cases, the automatically produced plan required manual 
adjustment, either because of errors in auto-segmentation of 
OARs, or due to a sub-optimal dose distribution. In general, 
RTT hands-on time reduced with up to 2 hours per plan, 
while maintaining plan quality. 
To prevent loss of knowledge and skills among RTTs, 10% of 
the requested plans for a tumor site are randomly assigned 
for manual treatment planning. In addition, planning 
challenges are organized in which a number of RTTs makes a 
treatment plan for the same patient. The results are 
discussed with all RTTs. 
 
Conclusion: Complete automation of the treatment planning 
process is feasible for selected tumor sites and results in 
considerable reduction of hands-on time. By designing new 
QA methods, loss of skills and knowledge among RTTs can be 
prevented, thus ensuring that RTTs remain capable of 
manually designing and/or adapting treatment plans. 
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Purpose or Objective: In definitive radiotherapy for cervical 
cancer, a HDR brachytherapy boost is most commonly used 
after external beam radiation (EBRT). While brachytherapy 
doses are chosen such that a cumulative EqD2 of 80 to 90Gy 
is delivered to the primary tumour after a 45 to 50.4Gy EBRT 
dose, there is less certainty regarding the brachytherapy dose 
contribution to pelvic lymph nodes. This poses a challenge as 
to how high a preceding EBRT dose should be prescribed to 
gross nodal disease, in order to achieve a cumulative 
tumoricidal effect.  
While the use of MRI guided 3-dimensional brachytherapy is 
increasing, the point-based Manchester system remains the 
most widely utilized technique. The objective of this study is 
to determine the brachytherapy dose contribution to 
individual pelvic lymph node regions, using CT planning with 
the Manchester system. 
 
Material and Methods: CT planning datasets from 40 patients 
who had undergone intracavitary HDR brachytherapy for 
stage III or IVA cervical cancer were retrieved. All patients 
received prior 3D conformal EBRT to a dose of 50.4Gy in 28 
fractions, followed by four fractions of CT-based 
brachytherapy, prescribing to Manchester point A. Half of the 
patients (n=20) received a brachytherapy dose of 5Gy per 
fraction, while the other half received 6Gy. Decision on 
brachytherapy dose was dependent on the ability to meet 
D2cc constraints for the adjacent organs-at-risk.  
Following international consensus guidelines, the right and 
left external iliac, internal iliac and obturator groups of 
lymph nodes were separately contoured on the CT dataset 
(see Figure 1). Applying the initial brachytherapy plan on the 
Oncentra TPS, mean doses to each nodal group according to 
laterality (i.e. left and right) were calculated for each 
patient, and both results combined to obtain the average 
mean dose to the entire nodal group. All individual patient 
results were then averaged across the respective study 
groups (5 and 6 Gy groups) and corresponding EqD2s 
calculated. 
 
 
 
Results: A summary of results is shown in Table 1.  
For patients who received a per fraction brachytherapy dose 
of 5 Gy, average mean absolute dose to the external iliac, 
internal iliac, and obturator nodal groups was 0.80 Gy, 1.12 
Gy and 1.34 Gy respectively. The corresponding EQD2s were 
0.72 Gy, 1.05 Gy, and 1.28 Gy respectively.  
For patients who received a per fraction brachytherapy dose 
of 6 Gy, average mean absolute dose to the external iliac, 
internal iliac, and obturator nodal groups was 1.16 Gy, 1.56 
Gy and 1.80 Gy respectively. The corresponding EQD2s were 
1.08 Gy, 1.50 Gy and 1.79 Gy respectively. 
 
